LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM
- Monday, November 7, 2022, 7:11
- PR Newswire
- Add a comment
TREVOSE, Pa., Nov. 7, 2022 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin…
About the Author
admin has written 20655 stories on this site.